<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BENZTROPINE MESYLATE</span><br/>(benz'troe-peen)<br/><span class="topboxtradename">Apo-Benztropine <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename"> Bensylate <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename"> Cogentin, </span><span class="topboxtradename"> PMS Benztropine <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">antiparkinsonism agent</span><br/><b>Prototype: </b>Levodopa<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg, 1 mg, 2 mg tablets; 1 mg/mL ampules</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic centrally acting anticholinergic (antimuscarinic) agent. Acts by diminishing excess cholinergic effect associated
         with dopamine deficiency.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Suppresses tremor and rigidity; does not alleviate tardive dyskinesia.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic treatment of all forms of parkinsonism (arteriosclerotic, idiopathic, postencephalitic) and to relieve extrapyramidal
         symptoms associated with neuroleptic drugs, e.g., haloperidol (Haldol), phenothiazines, thiothixene (Navane). Commonly used
         as supplement with trihexyphenidyl, carbidopa, or levodopa therapy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Narrow angle glaucoma; myasthenia gravis; obstructive diseases of GU and GI tracts; tendency to tachycardia; tardive dyskinesia,
         children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Older children, older adults or debilitated patients, patients with poor mental outlook, mental disorders; enlarged prostate;
         hypertension; history of renal or hepatic disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Parkinsonism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.51 mg/d, may gradually increase as needed up to 6 mg/d<br/><br/><span class="indicationtitle">Extrapyramidal Reactions</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12 mg b.i.d. <span class="rdroute">IM/IV</span> 12 mg as needed<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IM/IV</span>
<i>&gt;3 y</i>, 0.020.05 mg/kg, 12 times/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give immediately after meals or with food to prevent gastric irritation. Tablet can be crushed and sprinkled on or mixed with
            food.
         </li>
<li>Initiate and withdraw drug therapy gradually; effects are cumulative.</li>
<li>Store in tightly covered, light-resistant container at 15°30° C (59°86° F) unless otherwise
            directed.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to infants and children: Verify correct IV concentration with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 1 mg or a fraction thereof over 1 min.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Sedation</span>, drowsiness, dizziness, paresthesias; agitation, irritability, restlessness, nervousness, insomnia, hallucinations, delirium,
      mental confusion, toxic psychosis, muscular weakness, ataxia, inability to move certain muscle groups. <span class="typehead">CV:</span> Palpitation, tachycardia, flushing. <span class="typehead">Special Senses:</span> Blurred vision, mydriasis, photophobia. <span class="typehead">GI:</span> Nausea, vomiting, <span class="speceff-common">constipation, dry mouth,</span> distention, <span class="speceff-life">paralytic ileus</span>. <span class="typehead">Urogenital:</span> Dysuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b>Alcohol,</b>
<span class="classification">cns depressants</span> have additive sedation and depressant effects; <b>amantadine,</b>
<span class="classification">tricyclic antidepressants</span>, <span class="classification">mao inhibitors</span>, <span class="classification">phenothiazines</span>, <b>procainamide,</b>
<b>quinidine</b> have additive anticholinergic effects and cause confusion, hallucinations, paralytic ileus. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 15 min IM/IV; 1 h PO. <span class="typehead">Duration:</span> 610 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess therapeutic effectiveness. Clinical improvement may not be evident for 23 d after oral drug is started.</li>
<li>Monitor I&amp;O ratio and pattern. Advise patient to report difficulty in urination or infrequent voiding. Dosage reduction may
            be indicated.
         </li>
<li>Closely monitor for appearance of S&amp;S of onset of paralytic ileus including intermittent constipation, abdominal pain, diminution
            of bowel sounds on auscultation, and distention.
         </li>
<li>Monitor for and report muscle weakness or inability to move certain muscle groups. Dosage reduction may be needed.</li>
<li>Supervise ambulation and use bed side rails as necessary.</li>
<li>Report immediately S&amp;S of CNS depression or stimulation. These usually require interruption of drug therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known. Seek help walking as necessary.</li>
<li>Avoid alcohol and other CNS depressants because they may cause additive drowsiness. Do not take OTC cold, cough, or hay fever
            remedies unless approved by physician.
         </li>
<li>Sugarless gum, hard candy, and rinsing mouth with tepid water will help dry mouth.</li>
<li>Avoid doing manual labor or strenuous exercise in hot weather; diminished sweating may require dose adjustments because of
            possibility of heat stroke. This condition is most apt to occur in the older adults.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>